Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.
DeVries AA, Dennis J, Tyrer JP, Peng PC, Coetzee SG, Reyes AL, Plummer JT, Davis BD, Chen SS, Dezem FS, Aben KKH, Anton-Culver H, Antonenkova NN, Beckmann MW, Beeghly-Fadiel A, Berchuck A, Bogdanova NV, Bogdanova-Markov N, Brenton JD, Butzow R, Campbell I, Chang-Claude J, Chenevix-Trench G, Cook LS, DeFazio A, Doherty JA, Dörk T, Eccles DM, Eliassen AH, Fasching PA, Fortner RT, Giles GG, Goode EL, Goodman MT, Gronwald J; OPAL Study Group; AOCS Group; Håkansson N, Hildebrandt MAT, Huff C, Huntsman DG, Jensen A, Kar S, Karlan BY, Khusnutdinova EK, Kiemeney LA, Kjaer SK, Kupryjanczyk J, Labrie M, Lambrechts D, Le ND, Lubiński J, May T, Menon U, Milne RL, Modugno F, Monteiro AN, Moysich KB, Odunsi K, Olsson H, Pearce CL, Pejovic T, Ramus SJ, Riboli E, Riggan MJ, Romieu I, Sandler DP, Schildkraut JM, Setiawan VW, Sieh W, Song H, Sutphen R, Terry KL, Thompson PJ, Titus L, Tworoger SS, Van Nieuwenhuysen E, Edwards DV, Webb PM, Wentzensen N, Whittemore AS, Wolk A, Wu AH, Ziogas A, Freedman ML, Lawrenson K, Pharoah PDP, Easton DF, Gayther SA, Jones MR. DeVries AA, et al. Among authors: labrie m. J Natl Cancer Inst. 2022 Nov 14;114(11):1533-1544. doi: 10.1093/jnci/djac160. J Natl Cancer Inst. 2022. PMID: 36210504 Free PMC article.
Proteomics advances for precision therapy in ovarian cancer.
Labrie M, Kendsersky ND, Ma H, Campbell L, Eng J, Chin K, Mills GB. Labrie M, et al. Expert Rev Proteomics. 2019 Oct;16(10):841-850. doi: 10.1080/14789450.2019.1666004. Epub 2019 Sep 13. Expert Rev Proteomics. 2019. PMID: 31512530 Free PMC article. Review.
Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.
Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Labrie M, et al. Oncotarget. 2019 May 28;10(37):3533-3546. doi: 10.18632/oncotarget.26947. eCollection 2019 May 28. Oncotarget. 2019. PMID: 31191824 Free PMC article.
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.
Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Westin SN, et al. Among authors: labrie m. Clin Cancer Res. 2021 Dec 1;27(23):6354-6365. doi: 10.1158/1078-0432.CCR-21-1656. Epub 2021 Sep 13. Clin Cancer Res. 2021. PMID: 34518313 Free PMC article. Clinical Trial.
Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics.
Li A, Keck JM, Parmar S, Patterson J, Labrie M, Creason AL, Johnson BE, Downey M, Thomas G, Beadling C, Heiser LM, Kolodzie A, Guimaraes AR, Corless CL, Gray JW, Mills GB, Bergan RC, Mitri ZI. Li A, et al. Among authors: labrie m. NPJ Precis Oncol. 2021 Mar 26;5(1):28. doi: 10.1038/s41698-021-00165-4. NPJ Precis Oncol. 2021. PMID: 33772089 Free PMC article.
Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer.
Parmar S, Keck JM, Kong B, Look R, Johnson B, Patterson J, Labrie M, Guimaraes AR, Corless CL, Beadling C, Kolodzie A, Bergan R, Gray JW, Mills GB, Mitri ZI. Parmar S, et al. Among authors: labrie m. JCO Precis Oncol. 2021 Jan 8;5:PO.20.00183. doi: 10.1200/PO.20.00183. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34250408 Free PMC article. No abstract available.
Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies.
Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, Coussens LM, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI. Labrie M, et al. NPJ Precis Oncol. 2021 Oct 19;5(1):92. doi: 10.1038/s41698-021-00232-w. NPJ Precis Oncol. 2021. PMID: 34667258 Free PMC article.
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.
Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J, Sadek N, Xiao M, Zhang J, Labrie M, Randell S, Beroard A, Sugarman E, Rebecca VW, Wei Z, Lu Y, Mills GB, Field J, Villanueva J, Xu X, Herlyn M, Guo W. Wang B, et al. Among authors: labrie m. Oncogene. 2021 Sep;40(37):5590-5599. doi: 10.1038/s41388-021-01911-5. Epub 2021 Jul 24. Oncogene. 2021. PMID: 34304249 Free PMC article.
55 results